Sign in
CompletedNo phase

Prospective Clinical Evaluation of COVID/Flu Detect™ Rapid Self-Test in Symptomatic Subjects for Non-Prescription Over-the-Counter (OTC) Use

Key facts

Who runs it
InBios International, Inc.
Where
Birmingham, Boise, Miami, Midland, New York, Odessa, St Louis, and The Bronx, United StatesSee the 10 sites
Trial code
Status
Completed
People taking part
899 people enrolled
Started
26 Dec 2024
Ended
19 May 2025
Type of study
Observational
Treatments tested
  • COVID/Flu Detect™ Rapid Self-Test
Record updated
22 May 2025

Who can take part

Age
2 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Subjects must be at least 18 years of age, or at least 2 years of age and accompanied by parent or legal guardian
  • Subjects must be willing and able to give informed consent or assent (as age-appropriate)
  • Subjects must be able to read/speak English (or Spanish at specific sites) if subject is an adult, minor aged 14 years or older, or parent/guardian of a child subject aged 2 through 13 years
  • Subjects must be currently exhibiting at least two of the following symptoms consistent with possible SARS-CoV-2 or influenza infection: fever or feeling feverish (in absence of documented fever), chills, cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, nasal congestion or runny nose, nausea or vomiting, and/or diarrhea. Subjects must be within 5 days of symptoms onset at enrollment (the day that symptoms start is day 0)

Who cannot take part

  • Subject was previously enrolled in this study
  • Subject has received results of an influenza or COVID-19 test within the previous 5 days
  • Subject has undergone a nasal wash or nasal aspirate procedure on day of enrollment
  • Subject has an active nosebleed

Where in United States

  • Cahaba ResearchBirmingham, United States
  • ASR, LLCBoise, United States
  • Medicus Health Research Group IncMiami, United States
  • Eastside Research AssociatesMidland, United States
  • Ichan School of Medicine at Mount Sinai, Department of Emergency MedicineNew York, United States
  • ERA Health ResearchOdessa, United States
  • Barnes-Jewish HospitalSt Louis, United States
  • St. Louis Children's HospitalSt Louis, United States
  • Washington University School of MedicineSt Louis, United States
  • CHEAR Center LLCThe Bronx, United States

About the trial

What the trial wants to find out

The goal of this study is to evaluate the performance of the COVID/Flu Detect™ Rapid Self-Test when used in a home-like setting by lay users. The COVID/Flu Detect™ Rapid Self-Test is an investigational device intended for the qualitative detection and differentiation of SARS-CoV-2, influenza A, and influenza B protein antigens in nasal swab samples. Participants who are aged two (2) years and older and have symptoms of respiratory illness consistent with SARS-CoV-2 and influenza infection may be enrolled. Participants will use the COVID/Flu Detect™ Rapid Self-Test to self-collect, self-test, and interpret the results. Participants will have a nasal swab sample collected by a healthcare provider for comparator testing by PCR tests for SARS-CoV-2, influenza A, and influenza B. Researchers will compare the results of the COVID/Flu Detect™ Rapid Self-Test obtained by the participants to results from the PCR comparator tests to evaluate performance.

Treatments tested

  • COVID/Flu Detect™ Rapid Self-Test

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
22 May 2025